These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 7811540)
1. Resistance, drug failure, and disease progression. Richman DD AIDS Res Hum Retroviruses; 1994 Aug; 10(8):901-5. PubMed ID: 7811540 [TBL] [Abstract][Full Text] [Related]
2. Combination therapy: more effective control of HIV type 1? Johnson VA AIDS Res Hum Retroviruses; 1994 Aug; 10(8):907-12. PubMed ID: 7811541 [TBL] [Abstract][Full Text] [Related]
3. Studies of zidovudine in combination with didanosine and zalcitabine. Jablonowski H J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509 [TBL] [Abstract][Full Text] [Related]
4. Nevirapine triple combo results released. Common Factor; 1995 Apr; (no 10):21. PubMed ID: 11362346 [TBL] [Abstract][Full Text] [Related]
6. Viral resistance: a major challenge in managing HIV disease. Boucher CA; Reedijk M J Biol Regul Homeost Agents; 1995; 9(3):91-4. PubMed ID: 8782014 [No Abstract] [Full Text] [Related]
7. 3TC/AZT: just another combination. GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362997 [TBL] [Abstract][Full Text] [Related]
8. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. D'Aquila RT; Johnson VA; Welles SL; Japour AJ; Kuritzkes DR; DeGruttola V; Reichelderfer PS; Coombs RW; Crumpacker CS; Kahn JO; Richman DD Ann Intern Med; 1995 Mar; 122(6):401-8. PubMed ID: 7856987 [TBL] [Abstract][Full Text] [Related]
9. Conference looks at HIV drug resistance. Chang HE GMHC Treat Issues; 1995 Sep; 9(9):6-8. PubMed ID: 11362910 [TBL] [Abstract][Full Text] [Related]
10. Influence of emergence of viral resistance on HIV treatment choice. Moyle G Int J STD AIDS; 1995; 6(3):225-6. PubMed ID: 7647133 [No Abstract] [Full Text] [Related]
11. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. Zhu QY; Scarborough A; Polsky B; Chou TC AIDS Res Hum Retroviruses; 1996 Apr; 12(6):507-17. PubMed ID: 8679306 [TBL] [Abstract][Full Text] [Related]
12. Managing HIV. Part 4: Primary therapy. 4.1 Antiretroviral therapies for HIV. Crowe S; Cooper DA; Chambers DE Med J Aust; 1996 Mar; 164(5):290-5. PubMed ID: 8628165 [TBL] [Abstract][Full Text] [Related]
13. Triple combination superior to double combination. Grodeck B Posit Aware; 1995; ():6. PubMed ID: 11362210 [TBL] [Abstract][Full Text] [Related]
14. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778 [TBL] [Abstract][Full Text] [Related]
15. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group. Lancet; 1999 Jun; 353(9169):2014-25. PubMed ID: 10376616 [TBL] [Abstract][Full Text] [Related]
16. Protease inhibitors and prevention of cross resistance. Levin J AIDS Treat News; 1995 Oct; (no 232):1-3. PubMed ID: 11362875 [TBL] [Abstract][Full Text] [Related]